Showing results (101-110 of 506) with videos related to
Sort By:
Pageof 51
Circulation Research|April 30, 2016
Evolving Treatments for Arterial and Venous Thrombosis: Role of the Direct Oral AnticoagulantsNoel C Chan, John W Eikelboom, Jeffrey I WeitzThrombosis and Haemostasis|January 12, 2013
Zinc: an important cofactor in haemostasis and thrombosisTrang T Vu, James C Fredenburgh, Jeffrey I WeitzChest|February 9, 2012
New antithrombotic drugs: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice GuidelinesJeffrey I Weitz, John W Eikelboom, Meyer Michel SamamaCurrent Opinion in Hematology|July 7, 2011
Factor XI and XII as antithrombotic targetsFelicitas Müller, David Gailani, Thomas RennéTrends in Cardiovascular Medicine|November 30, 2002
Antithrombin-independent anticoagulation by hypersulfated low-molecular-weight heparinJames C Fredenburgh, Julia A M Anderson, Jeffrey I WeitzCurrent Opinion in Hematology|June 13, 2017
Single-chain factor XII: a new form of activated factor XIIIvan Ivanov, Anton Matafonov, David GailaniJournal of Thrombosis and Haemostasis : JTH|October 27, 2020
Proteolytic activity of contact factor zymogensAleksandr Shamanaev, Jonas Emsley, David GailaniHematology. American Society of Hematology. Education Program|November 25, 2004
Thrombophilia and new anticoagulant drugsJeffrey I Weitz, Saskia Middeldorp, William Geerts, et al.The Journal of Biological Chemistry|May 25, 2006
Heparin synergistically enhances interleukin-11 signaling through up-regulation of the MAPK pathwayRaghav Rajgopal, Martin Butcher, Jeffrey I Weitz, et al.Thrombosis and Haemostasis|February 21, 2022
State-of-the-Art Mini Review: Dual-Pathway Inhibition to Reduce Arterial and Venous ThromboembolismMark Goldin, Ioannis Koulas, Jeffrey I Weitz, et al.Pageof 51